QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VI, Clinical Trials and ICSR Management

Test your understanding of the concepts covered by GVP Module VI: Clinical Trials and ICSR Management.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the correct basis for assessing whether a suspected reaction is unexpected for SUSAR purposes?

The MAH's latest core safety information, regardless of the trial documents The applicable, controlled reference safety information for the investigational medicinal product The investigator's personal experience with the product Whether the reaction has ever been reported in any country

Question 2 of 10 A medicinal product is authorised, but it is being studied in an interventional clinical trial governed by the Clinical Trials Regulation. Which conclusion is most appropriate?

Every adverse reaction in the trial must automatically be processed as an EVPM case The product's authorisation means that clinical-trial safety reporting no longer applies The trial's legal and methodological classification must be assessed; applicable clinical-trial obligations may continue to apply The MAH automatically becomes the sponsor for all safety reporting

Question 3 of 10 Which feature is most important in reconciliation between separate sponsor and MAH safety systems?

Ensuring every record is duplicated identically in both systems Confirming that relevant information requiring action is transmitted accurately and discrepancies are investigated and resolved Comparing only the number of cases in each database once per year Restricting reconciliation to cases already submitted to EVPM

Question 4 of 10 What should be established before selecting the operational pathway for a safety report arising in a clinical trial?

Whether the product has a marketing authorisation The applicable legal and regulatory framework governing the trial Whether the event was reported by an investigator or a patient Whether the MAH has already entered the event into its database

Question 5 of 10 What is the principal distinction between EVCTM and EVPM in the context described by the article?

EVCTM is used for clinical-trial SUSARs, whereas EVPM is used for post-authorisation ICSRs EVCTM is used only by regulators, whereas EVPM is used only by sponsors EVCTM contains aggregate reports, whereas EVPM contains only clinical-trial reports EVCTM is the legacy database, whereas EVPM is the current CTIS application system

Question 6 of 10 Which responsibility remains with the sponsor even when clinical-trial safety activities are delegated to a CRO?

No responsibility, because delegation transfers regulatory accountability Oversight of the CRO and assurance that the trial safety system operates effectively Only responsibility for archiving, while the CRO owns all reporting decisions Responsibility for MAH post-authorisation reporting instead of the MAH

Question 7 of 10 An unexpected increase in the incidence of serious reactions that are individually expected is identified in a trial. How should this information initially be conceptualised?

It is automatically a SUSAR because the reactions are serious It may be an unexpected event affecting the trial benefit-risk balance and is distinct from a SUSAR It is irrelevant unless an individual case is reported to EVPM It should be treated as a medication error

Question 8 of 10 How should a medication error or misuse in a clinical trial be assessed?

It is automatically a SUSAR because the exposure was outside intended use It should be assessed as a circumstance and in relation to any resulting clinical consequence and applicable expedited criteria It should never be collected because it is not a reaction It must be reported to EVPM regardless of outcome or seriousness

Question 9 of 10 For a current EU clinical trial governed by Regulation (EU) No 536/2014, where should a SUSAR generally be reported?

EVPM as an ordinary post-authorisation ICSR EudraCT as the current application and safety system EudraVigilance through the clinical-trial functionality, EVCTM Only to the MAH, which then determines whether to report it

Question 10 of 10 Which statement best reflects the current role of EudraCT?

It is the current application system for all new EU/EEA clinical trials It is the current EudraVigilance module for post-authorisation ICSRs It is principally relevant to legacy clinical-trial records and certain continuing functions rather than serving as the current application system for new EU/EEA trials It has replaced CTIS for trials conducted after marketing authorisation

Knowledge Assessment: GVP Module VI, Clinical Trials and ICSR Management

Cookie Settings